Moreover, the impact of more stable 89Zr binding was demonstrated in the HER2-positive BT-474 bone model of metastases at 144 h p.i. In tibiae without tumour involvement, the uptake of [89Zr]Zr-DFO*-NCS-trastuzumab and the non-binding control [89Zr]Zr-DFO*-NCS-B12 was equally low and comparable (1.6 ± 0.2 and 1.5 ± 0.3%ID/g, respectively), which appeared to be similar to the uptake of [89Zr]Zr-DFO*-NCS-B12 in tumour-involved tibiae (1.8 ± 0.3%ID/g). This evidence concerns the gene ERBB2 and neoplasm.